Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 6 Similar Profiles
Ovarian Neoplasms Medicine & Life Sciences
Breast Neoplasms Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Platinum Medicine & Life Sciences
Carboplatin Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1979 2018

Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer

Litvak, A., Batukbhai, B., Russell, S. D., Tsai, H. L., Rosner, G. L., Jeter, S. C., Armstrong, D., Emens, L. A., Fetting, J., Wolff, A. C., Silhy, R., Stearns, V. & Connolly, R. M. Jan 1 2018 (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

Breast Neoplasms
Therapeutics
Confidence Intervals
Stroke Volume
Incidence

A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers

Reiss, K. A., Herman, J. M., Armstrong, D., Zahurak, M., Fyles, A., Brade, A., Milosevic, M., Dawson, L. A., Scardina, A., Fischer, P., Hacker-Prietz, A., Kinders, R. J., Wang, L., Chen, A., Temkin, S., Horiba, N., Stayner, L. A., Siu, L. L. & Azad, N. S. Mar 1 2017 In : Gynecologic Oncology. 144, 3, p. 486-490 5 p.

Research output: Contribution to journalArticle

Fallopian Tube Neoplasms
Radiotherapy
Carcinoma
Neoplasms
Platinum

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience

Oliver, K. E., Brady, W. E., Birrer, M., Gershenson, D. M., Fleming, G., Copeland, L. J., Tewari, K., Argenta, P. A., Mannel, R. S., Secord, A. A., Stephan, J. M., Mutch, D. G., Stehman, F. B., Muggia, F. M., Rose, P. G., Armstrong, D. K., Bookman, M. A., Burger, R. A. & Farley, J. H. 2017 (Accepted/In press) In : Gynecologic Oncology.

Research output: Contribution to journalArticle

Platinum
Ovarian Neoplasms
Disease-Free Survival
Carcinoma
Survival

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial

Coleman, R. L., Brady, M. F., Herzog, T. J., Sabbatini, P., Armstrong, D. K., Walker, J. L., Kim, B. G., Fujiwara, K., Tewari, K. S., O'Malley, D. M., Davidson, S. A., Rubin, S. C., DiSilvestro, P., Basen-Engquist, K., Huang, H., Chan, J. K., Spirtos, N. M., Ashfaq, R. & Mannel, R. S. 2017 (Accepted/In press) In : The Lancet Oncology.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Platinum
Ovarian Neoplasms
Drug Therapy
Myositis
Rheumatic Diseases
Autoantibodies
Dermatomyositis
Breast Neoplasms